Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 6/20 | 0.62 |
| ▸ | GHSR | Q92847 | 2/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.59 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.59 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.59 |
| ▸ | ITGAL | P20701 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9653545 | 1.00 | ECE1 (0.62) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL30052260 | 0.96 | GHSR (0.62) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL31606505 | 0.94 | GHSR (0.65) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL29533411 | 0.93 | GHSR (0.65) | ECE1GHSRITGB2ICAM1ITGAL | |
| SCHEMBL29657708 | 0.92 | ERAP2 (0.62) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL30223334 | 0.92 | GHSR (0.57) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL30834217 | 0.92 | ECE1 (0.56) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL30736101 | 0.91 | MMP2 (0.60) | ECE1GHSR | |
| SCHEMBL21641802 | 0.91 | ITGB2 (0.67) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL21641801 | 0.91 | ITGB2 (0.67) | ECE1GHSRERAP2ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0204374-B1 | TRIPEPTIDIC COMPOUNDS HAVING HYPOTENSIVE ACTIVITY | POLIFARMA S.p.A. (IT) | 1992-12-30 | — | — | EP | claimed |
| US-5051404-A | Tripeptides of pyroglutamic acid, proline, tryptophan, phenylalanine or tyrosine and a natural aminoacid | ENIRICERCHE, S.P.A. (IT) | 1991-09-24 | — | — | US | claimed |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| EP-0204374-B1 | TRIPEPTIDIC COMPOUNDS HAVING HYPOTENSIVE ACTIVITY | POLIFARMA S.p.A. (IT) | 1992-12-30 | — | — | EP | disclosed |
| US-5051404-A | Tripeptides of pyroglutamic acid, proline, tryptophan, phenylalanine or tyrosine and a natural aminoacid | ENIRICERCHE, S.P.A. (IT) | 1991-09-24 | — | — | US | disclosed |
| EP-0204374-A2 | Tripeptidic compounds having hypotensive activity | POLIFARMA S.p.A. (IT) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | ECE1 1503/4885GHSR 1894/4885ERAP2 638/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | ECE1 1900/4885GHSR 1832/4885ERAP2 1822/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | ECE1 1900/4885GHSR 1832/4885ERAP2 1822/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | ECE1 1503/4885GHSR 1894/4885ERAP2 638/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | ECE1 1503/4885GHSR 1894/4885ERAP2 638/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | ECE1 1317/4885GHSR 1457/4885ERAP2 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.